134 related articles for article (PubMed ID: 29783394)
1. From blockbuster medicine to personalized medicine.
Jørgensen JT
Per Med; 2008 Jan; 5(1):55-63. PubMed ID: 29783394
[TBL] [Abstract][Full Text] [Related]
2. Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2008 Nov; 8(6):689-95. PubMed ID: 18999921
[TBL] [Abstract][Full Text] [Related]
3. The new era of personalized medicine: 10 years later.
Jørgensen JT; Winther H
Per Med; 2009 Jul; 6(4):423-428. PubMed ID: 29783540
[TBL] [Abstract][Full Text] [Related]
4. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
5. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
6. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.
Jørgensen JT
Oncologist; 2019 Jul; 24(7):e432-e440. PubMed ID: 30940745
[TBL] [Abstract][Full Text] [Related]
7. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
Scattereggia J
IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
[TBL] [Abstract][Full Text] [Related]
8. The faces of personalized medicine: a framework for understanding its meaning and scope.
Redekop WK; Mladsi D
Value Health; 2013; 16(6 Suppl):S4-9. PubMed ID: 24034312
[TBL] [Abstract][Full Text] [Related]
9. Challenges of drug discovery for personalized medicine.
Jain KK
Curr Opin Mol Ther; 2006 Dec; 8(6):487-92. PubMed ID: 17243483
[TBL] [Abstract][Full Text] [Related]
10. New ways of insulin delivery.
Heinemann L
Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
[TBL] [Abstract][Full Text] [Related]
11. Personalized medicine and ethics.
Josko D
Clin Lab Sci; 2014; 27(3):185-90. PubMed ID: 25219077
[TBL] [Abstract][Full Text] [Related]
12. Cognitive IT-systems for big data analysis in medicine.
Isakova J
Int J Risk Saf Med; 2015; 27 Suppl 1():S108-9. PubMed ID: 26639685
[TBL] [Abstract][Full Text] [Related]
13. Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.
Verlingue L; Alt M; Kamal M; Sablin MP; Zoubir M; Bousetta N; Pierga JY; Servant N; Paoletti X; Le Tourneau C
Per Med; 2014 Jul; 11(5):545-558. PubMed ID: 29758779
[TBL] [Abstract][Full Text] [Related]
14. Genetics/Genomics in chronic kidney disease--towards personalized medicine?
Luttropp K; Lindholm B; Carrero JJ; Glorieux G; Schepers E; Vanholder R; Schalling M; Stenvinkel P; Nordfors L
Semin Dial; 2009; 22(4):417-22. PubMed ID: 19708993
[TBL] [Abstract][Full Text] [Related]
15. Translational strategies to implement personalized medicine: rheumatoid arthritis examples.
Littman BH
Per Med; 2009 Jul; 6(4):429-437. PubMed ID: 29783543
[TBL] [Abstract][Full Text] [Related]
16. Personalized medicine: using effective partnering for managing the risk of legal liability.
Roth M
Per Med; 2007 Aug; 4(3):329-339. PubMed ID: 29788660
[TBL] [Abstract][Full Text] [Related]
17. Innovative tests for patient-tailored treatments: demonstrating value in the age of personalized medicine.
Housman L
Per Med; 2011 Mar; 8(2):183-189. PubMed ID: 29783409
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics--practice and challenges.
Ghosh R; Ghosh S; Chawla S
Aust Fam Physician; 2010 Oct; 39(10):788-90. PubMed ID: 20890484
[TBL] [Abstract][Full Text] [Related]
19. Can translational medicine bring us out of the R&D wilderness?
Milne CP
Per Med; 2009 Sep; 6(5):543-553. PubMed ID: 29783301
[TBL] [Abstract][Full Text] [Related]
20. Towards a balanced value business model for personalized medicine: an outlook.
Koelsch C; Przewrocka J; Keeling P
Pharmacogenomics; 2013 Jan; 14(1):89-102. PubMed ID: 23252951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
